WallachBeth Capital LLC

WallachBeth Capital LLC is a financial services firm specializing in institutional execution and capital markets services. Registered as a broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority (FINRA), the firm operates on a fully disclosed, agency-only basis, aiming to provide clients with unconflicted advice and intelligent trading solutions. Its primary operational hub is located in Jersey City, New Jersey.

The firm offers a comprehensive suite of services, including execution solutions for equities, exchange-traded funds (ETFs), derivatives, electronic trading, and outsourced trading. Additionally, WallachBeth Capital provides consulting and capital markets services, encompassing investment banking activities such as IPOs, private placements, and financial advisory. It caters to a diverse institutional client base, including hedge funds, asset managers, and insurance companies, with its capital markets division focusing on innovative small to medium-sized companies in the biotech, pharmaceutical, medtech, diagnostic, and telehealth sectors.

Led by CEO Michael Wallach and President/COO David Beth, WallachBeth Capital maintains its market position as a prominent agency execution firm. Recent activities include acting as the sole placement agent for bioAffinity Technologies, Inc.'s $4 million registered direct offering in October 2026, and the closing of Tenon Medical, Inc.'s $4.2 million public offering in July 2026. In November 2024, the firm adopted HUB Trading Operations to enhance its post-trade operational efficiency.